8-K: Tyra Biosciences Holds 2026 Annual Meeting, Elects Directors
Submission of Matters to a Vote of Security Holders
Tyra Biosciences announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class II directors and the ratification of its independent auditor.
Summary
- Tyra Biosciences held its 2026 Annual Meeting of Stockholders on May 28, 2026.
- Three Class II directors were elected for a three-year term expiring at the 2029 Annual Meeting.
- The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine corporate governance matters without new financial or strategic information.
Positives
- The election of directors and ratification of the auditor were approved by a significant majority of votes.
- Habib J. Dable received 44,242,803 votes for his election.
- Susan Moran, M.D., M.S.C.E. received 44,529,688 votes for her election.
- Robert More received 41,013,686 votes for his election.
- The appointment of Ernst & Young LLP was ratified with 53,092,820 votes for.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing, which pertains to the results of a shareholder meeting.
Industry Context
StockSavvy.ai notes that the routine election of directors and ratification of auditors are standard corporate governance procedures for publicly traded companies, indicating operational stability rather than strategic shifts.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class II Director | N/A | Habib J. Dable | 2026-05-28 | Election at 2026 Annual Meeting |
| Class II Director | N/A | Susan Moran, M.D., M.S.C.E. | 2026-05-28 | Election at 2026 Annual Meeting |
| Class II Director | N/A | Robert More | 2026-05-28 | Election at 2026 Annual Meeting |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Election of three Class II directors for a three-year term. | 2026-05-28 | Standard procedure to ensure board continuity and oversight. |
| Auditor Ratification | Ratification of Ernst & Young LLP as the independent registered public accounting firm. | 2026-05-28 | Confirms the company's commitment to independent financial auditing. |
Stakeholder Impact
- Shareholders: The election of directors and ratification of the auditor confirm the ongoing governance structure and oversight of the company.
Next Steps
- The elected directors will serve their three-year terms.
- Ernst & Young LLP will continue as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Dates
| Date | Description |
|---|---|
| 2026-05-28 | Date of the 2026 Annual Meeting of Stockholders. |
| 2026-12-31 | Fiscal year ending date for which Ernst & Young LLP was appointed as auditor. |
| 2029-05-28 | Term expiration date for the newly elected Class II directors. |
| 2026-06-02 | Date the Form 8-K was signed. |
Keywords
Tyra Biosciences, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Ernst & Young LLP, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.